TEDA Biomedical (08189) has issued a positive profit alert, projecting that the group will record a net profit attributable to shareholders of approximately RMB 7 million to RMB 10 million for the six months ended 30 June 2026, a sharp turnaround from the loss posted in the same period last year.

According to the company's announcement, revenue for the six-month period is expected to reach around RMB 290 million to RMB 300 million, representing an increase of approximately 28% to 33% compared with the revenue of about RMB 226 million recorded in the corresponding period in 2025. Meanwhile, the expected net profit attributable to owners of the company marks an improvement of roughly 209% to 256% against the loss of approximately RMB 6 million reported in the prior-year period, confirming a return to profitability.

The growth in both revenue and net profit during the reporting period was primarily driven by the rapid expansion of its AI life and health business segment. This division generated revenue of approximately RMB 100 million to RMB 110 million, contributing a net profit attributable to company owners of between RMB 10 million and RMB 12 million during the period.